1. Home
  2. Directory
  3. Oregon
  4. Eugene
  5. Optometrist
  6. NPI Profile
  7. Prescriptions 1982000808

DAVID NADEAU O.D.
Prescription History 1982000808
Optometrist in Eugene, OR

NPI Status: Active since November 05, 2014

Contact Information

1200 HILYARD ST STE 110
EUGENE, OR
ZIP 97401
Phone: (458) 205-6257
Fax: (458) 205-6255

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DAVID NADEAU O.D., an active Optometrist specialist practicing in Eugene, OR. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 201 documented patient claims. Among these therapy options, the most frequently utilized medication is Latanoprost, which accounts for 131 claims alone.

Medication Index

Brimonidine Tartrate

Generic Formulation: Brimonidine TartrateSpecialty: Optometry
Provider Metrics Summary
Total Claims 20
30-Day Fills 31.8
Days Supply 915
OR State Average Benchmarks
Peer Average Claims67.0
Peer Average 30-Day Fills127.7
Peer Average Days Supply3,718
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 70.1% less volume than the regional standard for practitioners inside OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,904.11 across this reporting matrix range.

Provider Avg Cost Per Claim

$95.21

State Avg Cost Per Claim

$31.28

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

This medication is used to treat open-angle glaucoma or high fluid pressure in the eye. Lowering high fluid pressure in the eye reduces the risk of vision loss, nerve damage, or blindness. This medication lowers pressure by allowing better fluid drainage from within the eye and also by reducing the amount of fluid formed in the eye. It is known as an alpha agonist. This drug is not recommended for use in children less than 2 years of age due to an increased risk of serious side effects such as very slowed breathing. Ask the doctor or pharmacist for details.

Brimonidine Tartrate-Timolol

Generic Formulation: Brimonidine Tartrate/TimololSpecialty: Optometry
Provider Metrics Summary
Total Claims 12
30-Day Fills 22.7
Days Supply 660
OR State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills31.5
Peer Average Days Supply882
Conservative Utilization

This provider writes prescriptions for this formulation 40.0% less frequently than the standard regional baseline metric for practitioners inside OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,659.51 across this reporting matrix range.

Provider Avg Cost Per Claim

$221.63

State Avg Cost Per Claim

$280.04

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of brimonidine tartrate and timolol maleate. The combined ADRENERGIC ALPHA2 RECEPTOR AGONIST and ADRENERGIC BETA-ANTAGONIST activity of these drugs reduce INTRAOCULAR PRESSURE in GLAUCOMA patients.

Therapeutic Applications

This combination medication is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This product contains brimonidine and timolol. These medications are used together when 1 drug is not controlling the pressure inside the eye. Brimonidine works by allowing better fluid drainage from within the eye and also by decreasing the amount of fluid formed in the eye. It belongs to a class of drugs known as alpha agonists. Timolol is thought to work by decreasing the amount of fluid formed in the eye. Timolol belongs to a class of drugs known as beta blockers. This medication is not recommended for use in children less than 2 years old due to an increased risk of serious side effects. Ask the doctor or pharmacist for more details.

Dorzolamide-Timolol

Generic Formulation: Dorzolamide Hcl/Timolol MaleatSpecialty: Optometry
Provider Metrics Summary
Total Claims 19
30-Day Fills 28.9
Days Supply 866
OR State Average Benchmarks
Peer Average Claims81.0
Peer Average 30-Day Fills171.3
Peer Average Days Supply5,117
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 76.5% less volume than the regional standard for practitioners inside OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $534.53 across this reporting matrix range.

Provider Avg Cost Per Claim

$28.13

State Avg Cost Per Claim

$30.51

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains two drugs used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers, and dorzolamide belongs to a class of drugs known as carbonic anhydrase inhibitors.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Optometry
Provider Metrics Summary
Total Claims 131
30-Day Fills 190.1
Days Supply 5,209
OR State Average Benchmarks
Peer Average Claims146.0
Peer Average 30-Day Fills255.9
Peer Average Days Supply7,273
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,995.71 across this reporting matrix range.

Provider Avg Cost Per Claim

$22.87

State Avg Cost Per Claim

$22.74

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Timolol Maleate

Generic Formulation: Timolol MaleateSpecialty: Optometry
Provider Metrics Summary
Total Claims 19
30-Day Fills 47.6
Days Supply 1,427
OR State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills24.6
Peer Average Days Supply736
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $329.72 across this reporting matrix range.

Provider Avg Cost Per Claim

$17.35

State Avg Cost Per Claim

$385.16

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A beta-adrenergic antagonist that is similar in action to PROPRANOLOL; the levo-isomer is more active. Timolol has been proposed as an anti-hypertensive, anti-arrhythmic, anti-angina, and anti-glaucoma agent. It is also used in the treatment of MIGRAINE DISORDERS and tremor.

Therapeutic Applications

This medication is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DAVID NADEAU O.D. provides transparency into local medical care patterns within Eugene, OR.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Optometrist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.